The Motley Fool··Howard SmithCompass Pathways Surges on Positive Phase 3 Psilocybin Trial Results
Compass Pathways stock surged 44% after positive Phase 3 trial results for psilocybin depression therapy. FDA application expected by end of 2024.
CMPSFDA approvaltreatment-resistant depression